RE:RE:RE:RE:Determining a Company’s Value - Old SchoolIt would be good to be confident that 'the tech is still on track' Rumpl but we had two scheduled Phase 1B Trials with Rutherrin and now there are none with one of those major indications (GBM) being entirely removed from the pipeline.
Also left wondering whether Roswell were denied consent to use TLD-1433 in NSCLC/mesothelioma or whether the drug itself didn`t make the cut?
Don`t feel anything like sufficiently informed to be able to make such an evaluation.